|
Intensive care units' prevention of pneumonia in critically-ill patients generally strong
May 21, 2008TORONTO, Ontario, Canada -- Mayo Clinic researchers found that the frequency with which critically-ill patients developed ventilator-associated pneumonia (VAP) is approximately the same at a multidisciplinary medical center such as Mayo Clinic compared to the average VAP-risk rate for 211 hospitals in the National Healthcare Safety Network (NHSN). This is good news for patients because it suggests that care levels are generally strong across the U.S. in intensive care units, which is where the sickest patients -- many of them elderly -- are treated. This is true despite variety in levels of care offered by individual hospitals.
The study also is helpful because it identified the fact that the VAP-risk rate for patients in a specific kind of intensive care unit, the trauma intensive care unit (TICU), was lower at Mayo Clinic, as compared to the NHSN average. This kind of finding is what the U.S. Centers for Disease Prevention and Control (CDC) intended when it made the NHSN data available in a June 2007 report. In that report, CDC analysts instructed hospitals to use the data to guide local prevention strategies and other quality improvement efforts aimed at reducing infection rates. The Mayo group presented its findings this week at the American Thoracic Society's 2008 International Conference in Toronto. The data showed that the Mayo Clinic risk rate for VAP in intensive care units (ICU) for trauma patients averaged 3.4 per 1,000 days of mechanical ventilation. This compares to the VAP average of 10.2 per 1,000 days in trauma ICUs participating in the NHSN.
The reason for this variation is not known, and the difference needs to be validated through further study. But these preliminary results identify a need for improvement to lower the 10.2 risk rate.
Significance of the Mayo Clinic Research
"The topic is an important one to study because developing VAP is a potential risk for all critically-ill patients who must be on an invasive mechanical ventilator greater than 48 hours," says Mayo lead author Ahmed Mahmoud, M.B.B.S.
"As the demographics of this country change, the number of frail elderly who end up hospitalized and needing ventilation in a TICU is likely to increase," adds senior author Bekele Afessa, M.D., of Mayo's pulmonary and critical care medicine group. "We want to do our best to eliminate the potential for any additional disease burden to patients. Understanding the risk of VAP in all ICU settings is a step toward that."
The Mayo study is the first to compare VAP-risk rates at (NHSN) hospitals to Mayo Clinic's experience as a single advanced medical center with integrated intensive care units and a unified approach to infection control. Mayo Clinic researchers studied 206 patients treated at Mayo Clinic's various ICUs between February and August 2007, and who consented to participate in the study.
Results
The Mayo Clinic comparison also showed that:
* The VAP-risk rate varies depending on the ICU medical specialty, from a low of 2.8 at Mayo Clinic's vascular/thoracic surgery intensive care unit and 5.7 in the analogous units of NHSN to a high of 10.2 per 1,000 ventilator days in NHSN trauma intensive care units.
* The Mayo VAP-risk data range from 2.8 to 8.2 across various kinds of ICUs at Mayo Clinic; 2.8 for vascular and thoracic surgery, 8.2 for neurology and 4.9 for cardiac surgery.
* Of the 19 bacteria isolated from the patients, the Mayo study found that the most common pathogen causing VAP was Pseudomonas aeruginosa. This information is helpful in determining the best antibiotic treatment for VAP. Acting on it could perhaps help prevent levels of VAP elsewhere.
Mayo Clinic
Significance of the Mayo Clinic Research
"The topic is an important one to study because developing VAP is a potential risk for all critically-ill patients who must be on an invasive mechanical ventilator greater than 48 hours," says Mayo lead author Ahmed Mahmoud, M.B.B.S.
"As the demographics of this country change, the number of frail elderly who end up hospitalized and needing ventilation in a TICU is likely to increase," adds senior author Bekele Afessa, M.D., of Mayo's pulmonary and critical care medicine group. "We want to do our best to eliminate the potential for any additional disease burden to patients. Understanding the risk of VAP in all ICU settings is a step toward that."
The Mayo study is the first to compare VAP-risk rates at (NHSN) hospitals to Mayo Clinic's experience as a single advanced medical center with integrated intensive care units and a unified approach to infection control. Mayo Clinic researchers studied 206 patients treated at Mayo Clinic's various ICUs between February and August 2007, and who consented to participate in the study.
Results
The Mayo Clinic comparison also showed that:
* The VAP-risk rate varies depending on the ICU medical specialty, from a low of 2.8 at Mayo Clinic's vascular/thoracic surgery intensive care unit and 5.7 in the analogous units of NHSN to a high of 10.2 per 1,000 ventilator days in NHSN trauma intensive care units.
* The Mayo VAP-risk data range from 2.8 to 8.2 across various kinds of ICUs at Mayo Clinic; 2.8 for vascular and thoracic surgery, 8.2 for neurology and 4.9 for cardiac surgery.
* Of the 19 bacteria isolated from the patients, the Mayo study found that the most common pathogen causing VAP was Pseudomonas aeruginosa. This information is helpful in determining the best antibiotic treatment for VAP. Acting on it could perhaps help prevent levels of VAP elsewhere.
Mayo Clinic
Pneumonia News and Current Pneumonia Events RSSVaccinated infants well protected against severe pneumococcal infection in Norway
Pneumococcus is a bacterium that can cause serious illnesses in some young children, e.g. meningitis, blood poisoning and pneumonia. Most of those who become ill are previously healthy without any known predisposing factors. The bacterium is present in the nose of up to 80 - 90% of healthy young children.
From foe to friend: Researchers use salmonella as a way to administer vaccines in the body
Researchers at the Biodesign Institute at Arizona State University have made a major step forward in their work to develop a biologically engineered organism that can effectively deliver an antigen in the body. The researchers report that they have been able to use live salmonella bacterium as the containment/delivery method for an antigen.
Yale researchers discover Legionnaire microbe's tricks
Yale University researchers have shed new light how bacteria like the ones that cause Legionnaires' disease and Q-fever raise such havoc in human patients.
Clinical study shows biological and clinical activity in relapsed leukemia patients
Finbarr Cotter, M.D., Ph.D., Professor of the Institute of Cell and Molecular Science at Barts and The London School of Medicine, today presented in an oral session "Clinical Caspase Activation in CLL by GCS-100: a Phase 2 Study" at the 10th International Conference on Malignant Lymphoma (10-ICML).
Despite vaccine, public should not get complacent about pneumococcal disease
Although the childhood pneumococcal conjugate vaccine has been a boon in reducing the incidence invasive pneumococcal disease (IPD), the public and the medical community must not get complacent, as non-vaccine strains, some resistant to antibiotics, are on the rise, say scientists at a meeting today in Boston.
Gene therapy increases survival for end-stage head and neck cancer
A gene therapy invented at The University of Texas M. D. Anderson Cancer Center is the first to succeed in a U.S. phase III clinical trial for cancer, as announced today at the American Society of Gene Therapy annual meeting in Boston.
Researchers explore the emerging role of infection in Alzheimer's disease
A number of chronic diseases are in fact caused by one or more infectious agents. For example, stomach ulcers are caused by Helicobacter pylori, chronic lung disease in newborns and chronic asthma in adults are both caused by Mycoplasmas and Chlamydia pneumonia, while some other pathogens have been associated with atherosclerosis.
Widespread airbag use could result in dramatic cost savings for US trauma centers
According to research published in the May issue of the Journal of the American College of Surgeons, the new generation of airbags not only helps protect motor vehicle collision (MVC) victims from injury and death, but also are associated with dramatic cost saving to trauma centers.
Gender disparity in community-acquired pneumonia
When men present in emergency departments with pneumonia, they are likely to be sicker than women and have a greater risk of dying over the next year, despite the more aggressive medical care they receive.
Men at increased risk of death from pneumonia compared to women
Men who come to the hospital with pneumonia generally are sicker than women and have a higher risk of dying over the next year, despite aggressive medical care.
More Pneumonia News Articles
| © 2008 BrightSurf.com |